Commerce and Industry Minister Suresh Prabhu (Photo | AFP) 
Business

Government wants to extend 'Make in India' plan to planes, drones: Suresh Prabhu

India is recording a healthy growth in passenger traffic as compared to China, which is the largest aviation market in the world.

From our online archive

NEW DELHI: The government wants to extend the 'Make in India' initiative to planes and drones and not just import the entire requirement in the coming years, Aviation Minister Suresh Prabhu said today.

India will need more than 1,300 planes in the next few years, he said.

"We do not want 1,300 planes to be bought from abroad. We will make them in India," he told PTI.

He said the ministry will work together with its defence counterparts to look at civilian and defence aircraft requirements.

The second priority, he said, is going to be drones as this sector holds huge potential.

"It is a big market and India has a huge potential for that. So we will work on drones," he added.

Using high-end technology like artificial intelligence and robotics in the airlines industry will be another priority area for the ministry, Prabhu said.

India is recording a healthy growth in passenger traffic as compared to China, which is the largest aviation market in the world.

The government has launched Udaan scheme, which is a regional connectivity scheme under which the government plans to provide connectivity to remote areas and enhance access in under-served regions.

The scheme has enabled the government to add 30 new airports on the aviation map in tier-2 and tier-3 cities under the first round.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’